HK1155185A1 - Human antibody molecules for il-13 il-13 - Google Patents

Human antibody molecules for il-13 il-13

Info

Publication number
HK1155185A1
HK1155185A1 HK11109456.5A HK11109456A HK1155185A1 HK 1155185 A1 HK1155185 A1 HK 1155185A1 HK 11109456 A HK11109456 A HK 11109456A HK 1155185 A1 HK1155185 A1 HK 1155185A1
Authority
HK
Hong Kong
Prior art keywords
human antibody
antibody molecules
molecules
human
antibody
Prior art date
Application number
HK11109456.5A
Other languages
Chinese (zh)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1155185A1 publication Critical patent/HK1155185A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11109456.5A 2003-07-15 2011-09-07 Human antibody molecules for il-13 il-13 HK1155185A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24

Publications (1)

Publication Number Publication Date
HK1155185A1 true HK1155185A1 (en) 2012-05-11

Family

ID=44535047

Family Applications (3)

Application Number Title Priority Date Filing Date
HK07101860.8A HK1097853A1 (en) 2003-07-15 2007-02-15 Human antibody molecules for il-13 il-13
HK11109456.5A HK1155185A1 (en) 2003-07-15 2011-09-07 Human antibody molecules for il-13 il-13
HK16104446.4A HK1216427A1 (en) 2003-07-15 2016-04-19 Human antibody molecules for il-13 il-13

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07101860.8A HK1097853A1 (en) 2003-07-15 2007-02-15 Human antibody molecules for il-13 il-13

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16104446.4A HK1216427A1 (en) 2003-07-15 2016-04-19 Human antibody molecules for il-13 il-13

Country Status (8)

Country Link
JP (3) JP5519567B2 (en)
KR (1) KR101073590B1 (en)
AU (1) AU2011200308B2 (en)
CY (1) CY1111467T1 (en)
HK (3) HK1097853A1 (en)
MX (1) MXPA06000258A (en)
NO (2) NO338853B1 (en)
RU (1) RU2009148270A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027797A2 (en) * 2014-06-18 2017-10-31 Medimmune Llc cell culture methods and media comprising n-acetylcysteine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142860A1 (en) * 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
JP4723810B2 (en) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド Hybrid antibody
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1534329A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Vaccine comprising il-13 and an adjuvant
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
MXPA06000258A (en) 2006-07-03
KR20060054312A (en) 2006-05-22
KR101073590B1 (en) 2011-10-14
JP2016047843A (en) 2016-04-07
NO338853B1 (en) 2016-10-24
CY1111467T1 (en) 2015-08-05
NO342727B1 (en) 2018-07-30
AU2011200308B2 (en) 2011-07-28
JP2011147454A (en) 2011-08-04
RU2009148270A (en) 2011-06-27
AU2011200308A1 (en) 2011-02-17
HK1216427A1 (en) 2016-11-11
HK1097853A1 (en) 2007-07-06
JP5922686B2 (en) 2016-05-24
JP5519567B2 (en) 2014-06-11
JP2014101372A (en) 2014-06-05
NO20160707A1 (en) 2016-04-27
NO20060730L (en) 2006-04-10

Similar Documents

Publication Publication Date Title
ME02245B (en) Anti-cd38 human antibodies and uses therefor
PL378412A1 (en) ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β
IL175773A0 (en) Anti-igfr1 antibody therapeutic combinations
PT1599504E (en) Modified antibody
IL173273A0 (en) Modified human igf-1r antibodies
HK1209759A1 (en) Ip-10 antibodies and their uses ip-10
IL175710A0 (en) Anti-mpl antibody
IL175608A0 (en) Antibodies
SI2511297T1 (en) Anti-CD38 human antibodies and uses therefor
EP1810979A4 (en) STABILIZED HUMAN IgG4 ANTIBODIES
EP1658095A4 (en) De-immunized anti-cd3 antibody
IL180789A0 (en) Human monoclonal antibodies against human il-4
SI1587542T1 (en) Use of anti-cd100 antibodies
ZA200606319B (en) Anti-CD38 human antibodies and uses therefor
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
EP1631315A4 (en) Antibodies which bind human cxcr3
IL172511A0 (en) Specific human antibodies
IL172510A0 (en) Antibodies and uses thereof
HK1216427A1 (en) Human antibody molecules for il-13 il-13
GB0306618D0 (en) Antibody
HK1209139A1 (en) Modified antibody
GB0325391D0 (en) Human monoclonal antibodies
SI1656391T1 (en) Modified human igf-1r antibodies
GB0329711D0 (en) Antibodies
GB0317974D0 (en) Novel antibodies

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240714